Is Entero Healthcar overvalued or undervalued?

As of 13 November 2025, Entero Healthcare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived investment potential. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 48.71, an EV to EBITDA of 26.44, and a PEG ratio of 0.34. These figures suggest that the stock price may not be justified by its earnings growth prospects. In comparison to its peers, Entero Healthcare's PE ratio significantly exceeds that of TCS at 22.34 and Infosys at 22.78, both of which are in the attractive and fair categories, respectively. Additionally, while Entero's EV to EBITDA ratio is higher than the industry average, it is worth noting that its ROCE stands at 7.86% and ROE at 5.50%, which are relatively low compared to the high valuation metrics. Despite a recent outperformance against the Sensex over the past week, the overall trend indicates that Entero Healthcare is overvalued in the current market context.